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Abstract 
Background: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder. Tyrosine kinase inhibitors 
(TKIs) are the standard treatments for CML, but a number of patients fail to respond effectively due to gene mutations. 
Celecoxib, a cyclooxygenase‑2 (COX‑2) inhibitor, has been shown to have anti‑tumor effect on solid tumor whereas 
the anti‑CML effect and its underlying mechanism have not been completely elucidated.
Methods: The cytotoxic effects of celecoxib and/or imatinib were evaluated by MTT assay. Cell cycle distribution was 
examined by propidium iodide (PI) assay. Apoptosis or necrosis was analyzed by Annexin‑V/PI, Hoechst 33342 staining 
and Western blot assays. Autophagy suppression effect of celecoxib was examined by Western blot and LysoTracker 
probe labelling. Lysosensor probe labelling was used to detect the effect of celecoxib on the lysosomal function.
Results: In this study, we found that celecoxib had therapy efficacy in KBM5 and imatinib‑resistant KBM5‑T315I CML 
cell lines. Celecoxib caused significant cytotoxic effect in both cell lines, especially in KBM5‑T315I cells exposed to 
celecoxib for 72 h. Moreover, celecoxib induced necrosis and apoptosis while inhibited autophagy in CML cell lines 
and patient samples. Furthermore, this study demonstrated that celecoxib prevented the autophagic flux by inhib‑
iting lysosome function. Celecoxib was tested in combination with imatinib, demonstrating that celecoxib could 
strengthen the cytotoxicity of imatinib in imatinib‑resistant CML cells.
Conclusions: These findings showed that celecoxib had therapy efficacy on CML cells. And it is first time to demon‑
strate that celecoxib is an autophagy suppresser and a combination of celecoxib and imatinib might be a promising 
new therapeutic strategy for imatinib‑resistant CML cells.
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Background
Chronic myelogenous leukemia (CML) is a hematologi-
cal stem cell disorder responsible for 15–20  % of newly 
diagnosed leukemia in adults. More than 90  % of CML 
patients are characterized by the Philadelphia chromo-
some carrying the Bcr-Abl fusion gene [1, 2]. Current 
therapeutic regimens include treatment by tyrosine 
kinase inhibitors (TKIs) and allogeneic hematopoietic 
stem cell transplantation (allo-HSCT) [3, 4]. Imatinib, 
recommended as a frontline therapy for chronic phase 
CML, gives a good clinical response. Unfortunately, 
some patients, especially in the progressive phase of the 
disease, show no response or relapse due to resistance. 
The major mechanism of imatinib resistance is a Bcr-Abl 
kinase domain mutation [5] and the existence of leuke-
mia stem cells [6]. Allo-HSCT is recommended as an ini-
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donors and is the only curative treatment as of today. 
However, not all patients are eligible for allo-HSCT. 
Therefore, it is critical to continue research for novel 
therapeutic approaches.
Celecoxib is a non-steroidal anti-inflammatory drugs 
(NSAIDs) and selective cyclooxygenase-2 (COX-2) 
inhibitor that is used to treat osteoarthritis and rheu-
matoid arthritis. Recent studies show that celecoxib can 
regress colon cancer xenografts [7] and enhance the effi-
cacy of chemotherapy [8] and/or radiation treatment [9]. 
Celecoxib has been approved by the FDA for the treat-
ment of familial adenomatous polyposis (FPA) to reduce 
the incidence of colon and rectal cancer [10]. Further-
more, its effects on esophagus, liver, breast, lung and 
prostate cancers have also been confirmed [11–15]. The 
antitumor effect of celecoxib is associated with cell cycle 
arrest, apoptosis and autophagy induction [16, 17]. How-
ever, there are only few studies on the effects of celecoxib 
on hematological malignancies. These studies revealed 
that celecoxib could inhibit the proliferation of lym-
phoma, acute leukemia or CML cells [18–21]. Celecoxib 
was reported to have anti-tumor effects on K562 and 
HL-60 leukemia cells demonstrated by cell-cycle arrest 
and cell apoptosis and the effects were synergistic with 
other chemotherapy medicines [19, 21]. However, the 
molecular mechanism of these anti-tumor effects has not 
been well elucidated.
Autophagy is a conserved catabolic process where 
cell constituents are incorporated into autophagosomes 
that fuse with lysosomes after which the contents are 
degraded and recycled [22]. The adaptor protein p62 
and LC3 are autophagy associated proteins [23, 24]. In 
tumorgenesis the function of autophagy is complex, it is 
not always pro-death but can also be pro-survival under 
conditions of cellular stress [25, 26]. Celecoxib could 
induce autophagy in solid tumors such as urothelial car-
cinoma and colorectal cancer and studies revealed that 
autophagy inhibition enhances cancer cell apoptosis [16, 
27]. However, the effect on autophagy of celecoxib in 
hematopoietic tumors has not been well established.
In this study, we examined the effect of celecoxib on 
cell proliferation, necrosis, apoptosis and autophagy 
in CML cell lines KBM5 and KBM5-T315I. The results 
showed that celecoxib had cytotoxic effect on KBM5 
and imatinib-resistant KBM5-T315I cells. Apoptosis 
and necrosis was induced as reported, however con-
trary to other reports [16, 17], autophagy was inhibited 
by celecoxib in the two cell lines. Furthermore, this study 
found that celecoxib could suppress the autophagic flux 
by preventing the lysosome function. At last, celecoxib 
was demonstrated to strengthen the cytotoxicity of 
imatinib in imatinib-resistant CML cells. So, celecoxib 
might serve as a new tool to enhance the antitumor activ-
ity of conventional therapeutic agents in imatinib-resist-
ant CML cells.
Methods
Cell line and primary CML cells
The human leukemia cell lines KBM5 and KBM5-T315I 
were gifts from Professor Peng Huang (M. D. Anderson 
Cancer Center, Houston, TX). Six samples of primary 
CML cells were obtained from patients with newly diag-
nosed CML (data of patients is shown in Table  1). All 
patients gave written informed consent for the use of 
cells for research purposes. In each case, the diagnosis 
was based on morphological and cytochemical staining 
and cytogenetic analyses.
Cell culture
The cells were maintained at 37  °C with 5  % CO2 in 
RPMI-1640 medium supplemented with 10  % fetal 
bovine serum (FBS). The cell culture media and supple-
ments were purchased from Gibco. For primary CML 
cells, mononuclear cells (BMMNCs) were isolated by 
means of Ficoll density gradient centrifugation.
Reagents and antibodies
Reagents included celecoxib (Pfizer, New York, NY), 
imatinib (Novartis Pharma, Basel, Switzerland), chlo-
roquine (Sigma, St. Louis, MO). LC3 antibody was 
purchased from Novus Biologicals (Littleton, CO), 
SQSTM1/p62 antibody was purchased from Santa Cruz 
Biotechnology (Dallas, TX). Antibodies against cleaved 
caspase-3, 4E-BP1, phospho-4E-BP1, mTOR, phospho-
mTOR were obtained from Cell Signaling Technology 
(Danvers, MA). HRP (horseradish peroxidase)-labeled 
goat anti-rabbit IgG and goat anti-mouse IgG were 
bought from Protein Tech Group (Chicago, IL). MTT 
[3-(4,5-dimethylthia-zol-2-yl)-2, 5-diphenyltetrazolium 
bromide], Hoechst 33342 and propidium iodide (PI) 
were obtained from Sigma (St. Louis, MO). Annexin V-PI 
apoptosis detection kit was provided by BD Biosciences 
Pharmingen (Franklin Lakes, NJ).
MTT assay
Cell viability was assessed by MTT assay. Cells were 
seeded in 96-well plates and treated with celecoxib and/
or imatinib for 24, 48 or 72  h. Then MTT was added 
and incubated for 4  h, followed by centrifugation at 
1500 rpm for 5 min. Supernatants were removed and the 
remaining MTT dye was solubilized with 200 μl DMSO. 
The optical density was measured at 490  nm using a 
multi-well plate reader (Micro-plate Reader; Bio-Rad, 
Hercules, CA).
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Cell cycle analysis
Cells were collected and fixed with 70  % ethanol at 
−20  °C overnight. Then cells were washed three times 
and stained with a mixture of PI (50  μg/ml), 0.2  % Tri-
ton X-100 and RNase inhibitor (100 μg/ml) for 15 min in 
the dark. Cell cycle analysis was performed using a FACS 
flow cytometer equipped with Modfit LT for Mac V2.0 
software (BD Biosciences, San Jose, CA).
Hoechst 33342 staining
Nuclear fragmentation was examined by Hoechst 33342. 
Cells treated with celecoxib for 24  h were stained with 
Hoechst 33342 (10  μg/ml) for 15  min at 37  °C. Slides 
were viewed using a fluorescence microscope. Two hun-
dred cells were counted for statistics.
Apoptosis analysis
According to the instruction, approximately 1 × 106 cells 
per well were treated with 0, 20, 40, 60 and 80 μM con-
centrations of celecoxib. Then cells were collected and 
stained with Annexin V/PI. Flow cytometry was used to 
analyze the percentage of Annexin V-/PI+ (necrosis), 
Annexin V+/PI- (early apoptosis) and Annexin V+/PI+ 
(late apoptosis) cells.
Western blot analysis
Cells were collected and total protein was isolated with 
lysis buffer. Equal amounts of protein were subjected 
to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to polyvinylidene 
difluoride membranes. The membranes were blocked 
and then incubated with antibodies. Subsequently, the 
membranes were incubated with a HRP-conjugated sec-
ondary antibody at room temperature for 1 h. Blots were 
detected with an enhanced chemiluminescence reagent 
(Sigma), according to the manufacturer’s instructions.
LysoTracker and Lysosensor labelling
Cells were harvested and stained with LysoTracker Green 
(50  nM, Cat. No. L7526, Invitrogen, Carlsbad,CA), 
LysoSensor Green (1  µM, Cat. No. L7535, Invitrogen, 
Carlsbad,CA), and LysoTracker ® Red DND-99 (75  nM, 
Cat. No. L7528, Invitrogen, Carlsbad, CA) dye for 30 min 
at 37 °C according to the instructions. Slides were imaged 
using confocal microscopy (ZEISS, Germany).
Statistics
All data were presented as mean ± SD of three determi-
nations. One-way ANOVA followed by Bonferroni mul-
tiple comparison was performed to assess the differences 
between two groups under multiple conditions. If the 
data failed the normality test, the Kruskal–Wallis one-
way ANOVA on ranks was used. A value of p < 0.05 was 
considered statistically significant. Jin’s formula was used 
to evaluate the synergistic effects of drug combinations. 
Jin’s formula is given as: Q = Ea + b/(Ea + Eb—Ea × Eb). 
Ea + b represents the cell proliferation inhibition rate of 
the combined drugs, while Ea and Eb represent the rates 
for each drug respectively. A value of Q = 0.85–1.15 indi-
cates a simple additive effect, while Q  >  1.15 indicates 
synergism.
Results
Cytotoxic effect of celecoxib on human CML cells
First, the cytotoxic effect of celecoxib and imatinib 
on CML cells was measured by MTT assay. Two cell 
lines were used for this, KBM5 an imatinib-sensitive 
cell line and KBM5-T315I an imatinib-resistant cell 
line with a T315I site mutation. They were exposed to 
0, 20, 40, 60 and 80 μM celecoxib for 24, 48 and 72 h, 
respectively. As shown in Fig. 1a–c, both celecoxib and 
imatinib had cytotoxic effect on the two cell lines in 
a concentration- and time-dependent manner. The 
IC50 values of imatinib at 24, 48 and 72 h were 0.8, 0.5 
and 0.3 μM for KBM5 cells and 5.7, 3.5 and 1.9 μM for 
KBM5-T315I cells, which verified imatinib resistance 
for KBM5-T315I cells. For celecoxib, the IC50 val-
ues in KBM5 at 24, 48 and 72  h were 40.4, 39.0 and 
39.5 μM and for KBM5-T315I cells were 50.7, 36.5 and 
28.5 μM.
Table 1 Characteristic of patients
P patient; Y year; M male; F female; CML-CP chronic myelogenous leukemia-chronic phase; CML-AP chronic myelogenous leukemia-acute phase; WBC white blood 
cells; HGB hemoglobin; PLT platelet
No. Age/sex Diagnose WBC (109/L) HGB (g/L) PLT (109/L) BCR/ABL Treatment Time of disease 
(month)
Survival
P1 43 Y/M CML‑CP 290 72 931 Positive Imatinib 11 Yes
P2 42 Y/F CML‑CP 282 77 673 Positive Imatinib 11 Yes
P3 32 Y/F CML‑CP 34 131 505 Positive Imatinib 10 Yes
P4 33 Y/M CML‑CP 165 85 396 Positive Dasatinib 10 Yes
P5 27 Y/M CML‑CP 288 68 560 Positive Imatinib 9 Yes
P6 63 Y/M CML‑AP 320 77 887 Positive Imatinib 21 No
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Fig. 1 The cytotoxic effect of celecoxib and imatinib on KBM5 and KBM5‑T315I cells. a–c KBM5 and KBM5‑T315I cells were treated with 0, 20, 40, 
60, 80 μM celecoxib or 0, 0.1, 0.2, 0.4, 0.8 μM imatinib for 24, 48, 72 h, then cell viability was measured by MTT assay. Data were mean ± SD (n = 3). 
*p < 0.05, **p < 0.01, ***p < 0.001
Page 5 of 13Lu et al. J Transl Med  (2016) 14:270 
We next tested the effect of celecoxib on primary CML 
cells. Mononuclear cells were separated from bone mar-
row cells or peripheral blood cells of CML patients (data 
of patients is shown in Table  1). The mononuclear cells 
were exposed to different concentration of celecoxib 
for 24 and 48 h. As shown in Fig. 2a, the primary CML 
cells were sensitive to celecoxib. About 46.3 ± 16.9 and 
63.3 ± 18.3 % viability of primary cells were suppressed 
by 100 μM celecoxib at 24 and 48 h.
Celecoxib arrests CML cells at cell cycle G1 phase
Flow cytometry analysis was used to determine the effect 
of celecoxib on the cell cycle for KBM5 and KBM5-
T315I cells. As shown in Fig.  3a, cells treated with dif-
ferent doses of celecoxib were arrested at G1 phase in a 
concentration-dependent manner. Treatment of KBM5 
cells with 80  μM celecoxib resulted in an increase in 
the percentage of cells at G1 phase, from 34.9 ±  4.7 to 
58.0 ± 2.5 %, with a reduction of cells at S phase (Fig. 3b 
left) (p  <  0.05). Similar results were found in KBM5-
T315I cells where the percentage of cells in the G1 phase 
went up from 43.2 ±  6.1 to 58.7 ±  6.4 % (Fig. 3b right, 
p < 0.05).
Celecoxib induces apoptosis and necrosis in CML cells
To test the ability of celecoxib to induce apoptosis in 
CML cells, cells were treated with celecoxib for 24 h and 
tested with flow cytometry. As shown in Fig. 4A (a), the 
amount of Annexin V+/PI+ (late apoptosis) and Annexin 
V-/PI+ (necrosis) stained cells were both increased as 
celecoxib was added to KBM5 and KBM5-T315I cells. 
When cells were treated with 80 μM celecoxib, the early 
and late apoptosis rates were 23.8  ±  9.1  % for KBM5 
and 39.7  ±  10.6  % for KBM5-T315I cells, respectively 
[Fig.  4A (b)]. The necrosis rates were 56.2  ±  5.8  % for 
KBM5 and 30.8  ±  3.7  % for KBM5-T315I when cells 
treated with 80 μM celecoxib [Fig. 4A (b)]. However, for 
CML patient 6 cells (p6) treated with celecoxib, the pro-
portion of Annexin V+/PI+ (late apoptosis) stained cells 
decreased and Annexin V-/PI+ (necrosis) stained cells 
accumulated (Fig.  2b). Hoechst 33342 dye was used to 
detect the nuclear morphology with fluorescence micros-
copy. As shown in Fig. 4B (a), the nuclei of untreated cells 
appeared round in shape, while celecoxib caused nuclear 
condensation and simultaneously induced morphologi-
cal changes in portions of the cells after 24 h. As shown 
in Fig. 4B (b), 76.1 ± 7.0 % KBM5 cells and 58.5 ± 4.8 % 
Fig. 2 The effect of celecoxib and imatinib on human CML patient samples. a Mononuclear cells extracted from human CML patient samples 
and were treated with 0, 40, 60, 80, 100 μM celecoxib or 0, 1.6, 3.2, 6.4, 12.8 μM imatinib for 24, 48 h, then followed with MTT assay. Data were 
mean ± SD (n = 5). **p < 0.01, ***p < 0.001. b The sixth human CML patient sample was treated with 0, 40, 60, 80, 100 μM celecoxib for 24 h. 
Annexin V/PI assays was performed by flow cytometry
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KBM5-T315I cells died when treated with 60  μM 
celecoxib. Western blot assay showed that the expression 
of cleaved caspase-3 protein was significantly up-regu-
lated in KBM5 and KMB5-T315I cells treated with 60 μM 
celecoxib for 24 h (Fig. 4C).
Celecoxib suppresses autophagy at its late stage in CML 
cells
LC3 and p62 proteins were detected as autophagy asso-
ciated markers. When autophagy is induced, the ratio of 
LC3-II to LC3-I protein level increases and the expres-
sion of protein p62 reduces due to degradation [28, 29]. 
As shown in Fig. 5a, when the concentration of celecoxib 
increased, the ratio LC3-II to LC3-I protein level was 
raised as well as the expression of protein p62. Moreover, 
the expression of LC3-II and p62 protein was up-regu-
lated in a time-dependent manner with celecoxib treat-
ment (Fig. 5b). The effect of celecoxib was also confirmed 
in CML patient samples (Fig.  5c). These results were 
not identical as the reports [16, 17, 27] that said that 
celecoxib could induce autophagy.
The mTOR signal pathway is the most important path-
way for autophagy formation [30]. However, there was 
no change in the expression of phosphorylated mTOR 
and 4EBP proteins when KBM5 and KMB5-T315I cells 
were treated with celecoxib (Fig.  5a). Next, the two cell 
lines were treated with chloroquine (CQ), an autophagy 
inhibitor which prevents the fusion of autophagosome 
with lysosome and lysomal protein degradation [31]. The 
expression of LC3-II proteins was up-regulated in 20 μM 
Fig. 3 Celecoxib arrests KBM5 and KBM5‑T315I cells at cell cycle G1 phase. a The two cell lines were treated with 0, 20, 40, 60, 80 μM celecoxib for 
24 h. Flow cytometry analysis was conducted for the cell‑cycle distribution. b The graph showed the percentage of cells in each stage of the cell 
cycle. Data were mean ± SD (n = 3). *p < 0.05, **p < 0.01
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CQ treated KBM5 and KMB5-T315I cells (Fig.  5d). CQ 
and celecoxib had the same effect on the expression of 
LC3-II. Furthermore, the two cells were treated with CQ 
combined with celecoxib. Figure  5d displays that LC3-
II expression was not increased in cells treated with CQ 
and celecoxib when compared with cells treated with 
Fig. 4 Celecoxib induces apoptosis and necrosis in KBM5 and KBM5‑T315I cells. KBM5 and KBM5‑T315I cells were treated with different concentra‑
tions of celecoxib for 24 h. A (a) Flow cytometry was used to test the apoptosis and necrosis. (b) The graph showed the percentage of Annexin V‑/
PI+ (necrosis) cells in left, and showed the Annexin V+/PI‑ (early apoptosis) and Annexin V+/PI+ (late apoptosis) cells in right. B (a) Hoechst 33342 
staining was used to examine the apoptosis cells. (b) The graph showed that the percentage of cells with nuclear fragmentation. C Western blotting 
analysis showed cleaved caspase‑3 fragment. Data were mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 5 Celecoxib suppresses autophagy in KBM5 and KBM5‑T315I cells. a KBM5 and KBM5‑T315I cells were treated with 0, 20, 40, 60 μM celecoxib 
for 24 h. b The two cell lines were treated with 40 μM celecoxib for 6, 12, 24, 48 h. c Two samples for human CML patients were incubated with 
80 μM celecoxib for 24 h. d KBM5 and KBM5‑T315I cells were added with 20 μM CQ and/or 40 μM celecoxib for 24 h. a–d Cell lysates were sub‑
jected to Western blot analysis with indicated antibodies. The results shown are representative of three independent experiments
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CQ alone. LysoTracker probes have been used to image 
acidic spherical organelles [32]. In our study, 40  μM 
celecoxib or 20  μM CQ treatment both enhanced the 
green LysoTracker (Cat. No. L7526) fluorescence inten-
sity (Fig. 6a).
Celecoxib suppresses autophagy by preventing lysosomal 
functions
Our data above suggest that celecoxib blocks the 
autophagic flux at the late stage of autophagy. Therefore 
the effect of celecoxib on lysosomal pH was tested. The 
LysoSensor reagent exhibits a pH-dependent increase in 
fluorescence intensity upon acidification [33, 34]. This is 
in contrast to the LysoTracker probes which exhibit flu-
orescence that is largely independent of pH. The orange 
fluorescence intensity of the LysoSensor (Cat. No. L7535) 
weakened in CML cells treated with 40 μM celecoxib or 
20 μM CQ, indicating the neutralization of the intralyso-
somal pH (Fig.  6b). Then, we stained the two cells with 
LysoTracker (Cat. No. L7528) and LysoSensor (Cat. No. 
Fig. 6 Celecoxib prevents lysosomal function. a KBM5 and KBM5‑T315I cells were treated with 20 μM CQ or 40 μM celecoxib for 24 h. Hoechst 
33342 staining and LysoTracker (Cat. No. L7526) probe labelling assay was used to detect autophagosomes amount and the fluorescence intensity 
was showed by confocal microscopy. b The cells were treated as above, then LysoSensor (Cat. No. L7535) probes labelling assay were conducted to 
determinate the pH value inside lysosome. The results shown are representative of three independent experiments
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L7535) simultaneously. As Additional file  1: Figure S1 
showed that LysoTracker (Cat. No. L7528) labelled red 
fluorescence increased as cells treated with celecoxib or 
CQ, however, the LysoSensor (Cat. No. L7535) labelled 
green fluorescence was not significantly changed.
Celecoxib enhances cytotoxicity of imatinib on KBM5‑T315I 
cells
KBM5 and KBM5-T315I cells were treated with celecoxib 
and imatinib simultaneously and were subsequently 
detected by the MTT assay to determine the cytostatic 
efficacy. As shown in Fig. 7a, combination treatment with 
imatinib and celecoxib had addictive even synergistic 
cytotoxicity effect in KBM5-T315I cells (Q  >  0.85), but 
not in KBM5 cells. Moreover, autophagy and apoptosis 
associated proteins were detected. Imatinib increased 
the ratio of LC3-II to LC3-I protein level and reduced 
the expression of p62, indicating that autophagy was 
induced. However, celecoxib could alleviate the effect of 
imatinib on autophagy by up-regulating p62 expression. 
Fig. 7 Celecoxib enhances cytotoxicity of imatinib on KBM5 and KBM5‑T315I cells. a The two cell lines treated with 0, 20, 40 μM celecoxib and 0, 
0.1, 0.2, 0.4, 0.8 μM Imatinib for 24 and 48 h were subjected to MTT assay. Data were mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001. b The 
two cell lines were exposed to 40 μM celecoxib and 0.4 μM Imatinib for 24 h and Western blot was conducted for the expression of LC3 and cleaved 
caspase 3. Three independent experiments were conducted, and representative data were shown
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Western blot displayed that the expression of cleaved cas-
pase-3 was significantly induced when cells were treated 
with 40  μM celecoxib combined with 0.4  μM imatinib 
(Fig. 7b).
Discussion
Celecoxib is a selective COX-2 inhibitor and its anti-
tumor effect has been reported in various cancers [7–
9]. In this paper, we demonstrated that the anti-tumor 
activities of celecoxib included cell cycle arrest, necro-
sis, apoptosis and autophagy suppression in KBM5 and 
KBM5-T315I cells. KBM5-T315I cell is a mutation line 
of KBM5 with a threonine to isoleucine mutation at 
position 315 in the Abl fragment of the Bcr-Abl kinase 
domain. This leads to an alteration of the enzymes active 
site and makes these cells resistant to the first and second 
generation of TKI [35]. Results showed that celecoxib 
caused cytotoxic effect in the two CML cell lines which 
was dose and time-dependent. When extending the 
celecoxib incubation time, the inhibition effect was 
stronger in KBM5-T315I cells than in KBM5 cells (Fig. 1), 
indicating that celecoxib might be used as a new thera-
peutic agents in imatinib-resistant CML. In accordance 
with other reports [19, 21], our findings also confirmed 
that the anti-tumor effect was mediated by cell-cycle 
arrest at G1 phase (Fig. 3), necrosis and apoptosis induc-
tion (Fig. 4) in CML cell lines.
It was interesting to find that celecoxib had an opposite 
effect on autophagy in CML to that in solid tumors as pre-
viously reported. Huang et al. [16] reported that celecoxib 
induced autophagy in human colon cancer cells and that 
autophagy inhibitors augmented drug-induced apoptosis. 
Huang et al. [27] also showed the same results in human 
urothelial carcinoma cells. However, in these studies, 
autophagy formation was demonstrated by looking at the 
LC3-II or Atg12–Atg5 protein levels but not by looking 
at the levels of the p62 protein. Autophagy is a degrada-
tive process that leads to the decomposition of intracel-
lular material in lysosomes [36] and the adaptor proteins 
p62 and LC3 are the most important markers of this 
process [23, 24]. The autophagic process can be divided 
into three steps, the formation of the autophagosomes, 
the fuse of autophagosomes and lysosomes and the deg-
radation of the autophagic cargo in autolysosomes. Pro-
tein p62 can bind to LC3 and ubiquitinated proteins to 
facilitate autophagic clearance and was degraded in 
autolysosome [37]. The level of p62 can be regulated by 
autophagy and accumulates in autophagy deficient cells 
[38]. Thus, p62 accumulates when autophagy is inhibited 
and decreased levels can be observed when autophagy 
takes place. In our study, a variety of approaches were 
used to determinate the effect of celecoxib on autophagy. 
Western blot displayed that the ratio of LC3-II to LC3-I 
and the level of p62 protein were all increased when cells 
were treated with celecoxib (Fig. 5a, b). The same results 
were obtained in CML patient samples (Fig.  5c). Given 
that detection the expression of LC3-II and the fluores-
cence intensity of LysoTracker probes are measuring dif-
ferent biological events in the autophagic process, they 
were surprisingly both up-regulated during autophagic 
process [32, 39]. In our study, celecoxib or CQ treatment 
both enhanced the LysoTracker fluorescence intensity, 
indicating an increased autophagosome amount (Fig. 6a). 
Multiple signal transduction mechanisms are known to 
regulate autophagy and the mTOR pathway is the most 
important one for autophagy formation [30]. However, 
the phosphorylated mTOR and 4EBP proteins, which 
indicate an activated mTOR pathway, were not changed 
in the system (Fig. 5a), demonstrating that autophagy was 
not induced by mTOR pathway. Therefore, these results 
imply that celecoxib inhibits the autophagic flux at its late 
stage.
CQ, an inhibitor of autophagy, prevents the fusion 
between autophagosomes and dilated lysosomes by alter-
ing the lysosomal pH [31]. In our study, the effect on 
autophagy by CQ was the same as the effect by celecoxib 
indicating that celecoxib worked as an autophagy inhibi-
tor (Fig. 5). Furthermore, the result that celecoxib did not 
promote the LC3-II level in CML cells which were pre-
treated with CQ sustained celecoxib to be an autophagy 
inhibitor (Fig. 5d). To move forward, the weakened fluo-
rescence intensity of the LysoSensor in CML cells treated 
with celecoxib demonstrated that celecoxib could pre-
vent lysosomal function by altering the lysosomal pH just 
like CQ to suppress autophagy (Fig.  6b). Furthermore, 
LysoTraker and LysoSensor dyes were stained simulta-
neously to CML cells treated with celecoxib or CQ. The 
result showed that LysoTraker fluorescence increased 
with LysoSensor fluorescence no significant change 
which was not consistent with the result of Fig. 6b (Addi-
tional file  1: Figure S1). We think the two dyes maybe 
have interaction effect when stained the CML cells simul-
taneously, or other unknown mechanisms need further 
investigation.
Autophagy has been suggested to play a paradoxi-
cal role in various cancers. In some types of tumor, 
autophagy shows a protective role against anticancer 
treatment, however, others go through autophagic cell 
death [40, 41]. In hematology, it has become clear that 
autophagy is one of the survival mechanisms for CML 
stem cells which are insensitive to all three generations 
of TKIs [42, 43]. Studies have shown that TKI induced 
autophagy in CML [44–46]. Sheng et  al. [45] showed 
that Bcr-Abl up-regulated activating transcription factor 
5 (ATF5) to stimulate mTORC1 transcription and that 
imatinib could promote autophagy by inhibition of the 
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PI3  K/Akt/mTORC1 pathway. Meanwhile, Yu et  al. [46] 
showed that imatinib induced autophagy through inhibi-
tion of the expression of microRNA-30a and by up-reg-
ulation of BECLIN1 and ATG5 expression, independent 
of the mTORC1 pathway. So, it is suggested that imatinib 
or other chemotherapeutic agents could benefit from 
the addition of autophagy inhibitors in the treatment 
of CML. Helgason et  al. [44] showed that autophagy 
inhibitors, such as CQ and 3-MA, could increase CML 
cell death with anti-leukemia drugs including crotoxin, 
SAHA, bafetinib, imatinib and dasatinib. In this study, 
the result showed that celecoxib enhanced the cytotox-
icity of imatinib in KBM5-T315I cells but not in KBM5 
cells (Fig. 7a). It may because that imatinib itself has good 
cytotoxicity effect on KBM5 cells, but has only slightly 
inhibition effect on KBM5-T315I cells. So, when com-
bination of imatinib with celecoxib, the addictive effect 
was just showed in KBM5-T315I cells. Nevertheless, 
apoptosis in cells treated with imatinib was enhanced by 
celecoxib (Fig.  7b). In common with other studies [47–
49], imatinib could induce autophagy which was allevi-
ated by celecoxib (Fig. 7b).
Conclusions
In summary, the present study has demonstrated sev-
eral features of celecoxib-induced cytotoxicity in both 
imatinib-sensitive and imatinib-resistant CML cells, 
namely cell cycle arrest, apoptosis and necrosis induc-
tion and autophagy inhibition. It is the first time to reveal 
that celecoxib acts as an autophagy inhibitor through its 
effects on the function of lysosomal in CML cell lines. 
Besides its role in cell cycle arrest and apoptosis induc-
tion, celecoxib appears to enhance the cytotoxicity of 
imatinib in imatinib-resistant CML cells. Thus, the use of 
celecoxib in combination with imatinib appears to be a 
promising approach for imatinib-resistant CML therapy, 
and deserves further investigation.
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